Cardiac Arrest News and Research

Latest Cardiac Arrest News and Research

Physio-Control decides to perform voluntary correction of LIFEPAK 15 monitor/defibrillators

Physio-Control, Inc., a wholly-owned subsidiary of Medtronic, Inc., (NYSE: MDT), announced today the U.S. Food and Drug Administration has classified the company's decision to perform a voluntary correction of LIFEPAK 15 monitor/defibrillators manufactured prior to December 16, 2009 as a Class I recall.

23 Apr 2010

ABRAXANE-bevacizumab combination therapy may exhibit potential in treatment of triple-negative breast cancers

Abraxis BioScience, Inc., a fully integrated biotechnology company, announced study results today that demonstrate a regimen of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) given in combination with bevacizumab (Avastin®) may have potential in the treatment of triple-negative breast cancers.

21 Apr 2010

Genetic defect in protein glycogenin can lead to cardiac arrest

Researchers have discovered a new disorder linked to heart problems that stems from a genetic defect in the protein glycogenin. In a worst case scenario, disruption of this protein's function can lead to cardiac arrest, which is exactly what happened to the young man whose case triggered the investigation at Sahlgrenska University Hospital at the University of Gothenburg, Sweden, that led to a brand new diagnosis.

20 Apr 2010

Victims of SCA treated with AEDs by bystanders have much greater chance of survival

Victims of sudden cardiac arrest who are treated with automated external defibrillators by bystanders have a much greater chance of survival than their counterparts, according to landmark research by the Resuscitation Outcomes Consortium, just published in the Journal of the American College of Cardiology.

16 Apr 2010

FDA grants marketing clearance for Cambridge Heart's MTWA OEM module

Cambridge Heart, Inc., today announced that it has received clearance from the U.S. Food and Drug Administration to begin marketing its Microvolt T-Wave Alternans (MTWA) OEM module. The MTWA OEM module is designed to work with existing cardiac stress test platforms distributed by other manufacturers. This FDA 510(k) clearance allows Cambridge Heart to begin marketing the MTWA OEM module integrated with the Q-Stress line of stress systems manufactured by Cardiac Science Corporation, Inc..

16 Apr 2010

Insurance status and heart attack, many patients not seeking needed help

The signs of a cardiac arrest may exist but if you are under insured or not insured there is good chance that you may not undertake the recommended life saving actions of getting professional help as soon as you can.

14 Apr 2010

Raised levels of carbon dioxide in blood may lead to ‘near death experiences’

Near death experiences (NDEs), reported to include sensations such as life flashing before the eyes, feelings of peace and joy, and apparent encounters with mystical entities, may be caused by raised levels of carbon dioxide in the blood. Researchers writing in BioMed Central's open access journal Critical Care investigated the unexplained events in 52 cardiac arrest patients.

8 Apr 2010

HCM: Questions to ask

While a jury awarded Tony and Angela Key, $1.6 million following a malpractice trial in the death of their 22-year-old son, Antwoine, a basketball player for Eastern Connecticut State University who collapsed and died during a game in 2005, it is a small measure of solace when a young life is cut short, particularly when the cause - hypertrophic cardiomyopathy (HCM) - could have been treated, had it been properly diagnosed.

3 Apr 2010

Therapeutic hypothermia helps save marathon cardiac arrest victim

Jay Yim, 21, had worked on improving his fitness since age 15. In preparation for this year's Los Angeles Marathon on March 21, the University of Southern California pre-med student had been training with a marathon club and regularly did 10-mile runs on his own.

3 Apr 2010

Cambridge Heart's fourth-quarter total revenue down 20%

Cambridge Heart, Inc., today reported results for its fourth quarter and year ended December 31, 2009. Full financial statements and corresponding commentary can be found in the Company's Form 10-K, which is expected to be filed with the Securities and Exchange Commission on March 31, 2010.

31 Mar 2010

Two EMBEDA video news releases misleading, warns FDA DDMAC

On October 8, 2009, King Pharmaceuticals, Inc. received a Warning Letter from the Division of Drug Marketing, Advertising, and Communications (DDMAC) at the Food and Drug Administration regarding two video news releases - EMBEDA Media backgrounder, and EMBEDA Visual Media Technology, for EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules for oral use C-II.

27 Mar 2010

Genetic variation associated with lower risk of sudden cardiac arrest:Study

Physician-scientists at the Cedars-Sinai Heart Institute have found that a genetic variation is associated with lower risk of sudden cardiac arrest, a disorder that gives little warning and is fatal in about 95 percent of cases. Findings will be published tomorrow by the Public Library of Science (PloS One).

25 Mar 2010

Sir James Black inventor of beta-blockers passes away

Sir James Black passed away on Monday after a long illness, he was 85. Sir James Black is credited as the inventor of the beta-blocker drugs in 1962. These are drugs which play an important role in the treatment of angina and heart attacks. They are regarded as one of the major medical breakthroughs of the 20th Century in Pharmacology. Born in Uddingston, Lanarkshire, Sir James Black studied medicine at St. Andrews University.

23 Mar 2010

Cameron Health initiates clinical trial of minimally invasive S-ICD System for patients at risk of SCA

Cameron Health, Inc. today announced the commencement of the company's pivotal clinical trial to gain U.S. approval of its Subcutaneous Implantable Defibrillator (S-ICD®) System. The minimally invasive S-ICD System is prescribed for use in patients at risk of Sudden Cardiac Arrest (SCA). The S-ICD System is unique in that the implantation of the system is entirely subcutaneous; no leads are in or on the heart.

19 Mar 2010

Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint

Abraxis BioScience, Inc. today announced that its randomized registrational Phase 3 clinical trial comparing ABRAXANE® (protein-bound paclitaxel) with Taxol® (paclitaxel) injection, both in combination with carboplatin, met the study’s primary endpoint by demonstrating that ABRAXANE showed a significant improvement in overall response rate as compared to Taxol, in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), as assessed by independent radiologist review.

17 Mar 2010

Obese patients face lower risk of sudden cardiac death compared to non-obese patients

Obesity has long been identified as a risk factor for cardiovascular disease and heart failure. But, a new study conducted by researchers at the University of Rochester Medical Center found that being skinny confers no advantage when it comes to the risk of dying suddenly from cardiac causes.

17 Mar 2010

Lipitor 80 mg may help reduce risk of major cardiovascular events in high-risk patients

Lipitor® (atorvastatin calcium) 80 mg was associated with a significantly reduced risk of major cardiovascular events compared with Lipitor 10 mg among patients with both coronary heart disease (CHD) and chronic kidney disease (CKD) who were obese or had metabolic syndrome. These data, from two sub-analyses of the Treating to New Targets (TNT) trial that were designed and completed following the completion of TNT, were presented today at the 59th Annual Scientific Session of the American College of Cardiology (ACC) in Atlanta, Ga.

16 Mar 2010

InnerPulse selects Dassault Systemes' Abaqus FEA software

Dassault Systèmes, a world leader in 3D and Product Lifecycle Management (PLM) solutions, today announced that InnerPulse, a medical device company pioneering a novel technology for those patients with cardiac rhythm disorders, has selected Abaqus finite element analysis (FEA) software from the SIMULIA to assist in development of their technology designed in SolidWorks CAD software.

16 Mar 2010

Tel Aviv University investigates cause and effects of SCA syndrome

Sudden Cardiac Arrest syndrome (SCA) is poorly understood, but it's a real danger for the otherwise young and healthy. For no apparent reason, the heart suddenly stops beating, and without treatment death may follow within minutes. It's why some athletes drop dead on the track and why a young man, without any warning, suddenly dies while sitting at his desk.

11 Mar 2010

Researchers to collaborate on the largest clinical trial of hypothermia for stroke

Researchers at Cedars-Sinai Medical Center in Los Angeles, the University of California, San Diego School of Medicine, and UTHealth's Medical School will collaborate on the largest clinical trial of hypothermia (brain cooling) for stroke to date.

10 Mar 2010

Cardiac Arrest News and Research

Latest Cardiac Arrest News and Research

Physio-Control decides to perform voluntary correction of LIFEPAK 15 monitor/defibrillators

ABRAXANE-bevacizumab combination therapy may exhibit potential in treatment of triple-negative breast cancers

Genetic defect in protein glycogenin can lead to cardiac arrest

Victims of SCA treated with AEDs by bystanders have much greater chance of survival

FDA grants marketing clearance for Cambridge Heart's MTWA OEM module

Insurance status and heart attack, many patients not seeking needed help

Raised levels of carbon dioxide in blood may lead to ‘near death experiences’

HCM: Questions to ask

Therapeutic hypothermia helps save marathon cardiac arrest victim

Cambridge Heart's fourth-quarter total revenue down 20%

Two EMBEDA video news releases misleading, warns FDA DDMAC

Genetic variation associated with lower risk of sudden cardiac arrest:Study

Sir James Black inventor of beta-blockers passes away

Cameron Health initiates clinical trial of minimally invasive S-ICD System for patients at risk of SCA

Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint

Obese patients face lower risk of sudden cardiac death compared to non-obese patients

Lipitor 80 mg may help reduce risk of major cardiovascular events in high-risk patients

InnerPulse selects Dassault Systemes' Abaqus FEA software

Tel Aviv University investigates cause and effects of SCA syndrome

Researchers to collaborate on the largest clinical trial of hypothermia for stroke

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Cardiac Arrest News and Research

Latest Cardiac Arrest News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in